HONG KONG – Splisense Ltd. has closed a $28.5 million series B financing that it said will support pipeline development including its lead antisense oligonucleotide candidate, SPL84-23, for the potential treatment of cystic fibrosis. The Jerusalem-based company, which develops mRNA-altering therapies for CF and other genetic pulmonary diseases, attracted support for the round from Orbimed, Israel Biotech Fund, Biotel Ltd. and the Cystic Fibrosis Foundation.